JNJ-79635322

JNJ-79635322 (WHO INN: ramantamig) is Johnson & Johnson's trispecific antibody for relapsed/refractory multiple myeloma. It binds two tumor antigens on myeloma cells at once (BCMA and GPRC5D) while grabbing T cells via CD3 [1][2][15]. The bet: hitting two tumor targets simultaneously should crush the antigen-escape problem that limits current BCMA and GPRC5D bispecifics, including J&J's own Tecvayli (teclistamab) and Talvey (talquetamab). Phase 1 data presented at ASCO 2025 showed a 73% overall response rate (ORR) across 124 evaluable patients and an 86% ORR at the recommended Phase 2 dose (RP2D, n=36), with a 100% ORR in the subset of 27 BCMA- and GPRC5D-naive patients at the RP2D. Phase 3 head-to-head programs against teclistamab and another anti-BCMAxCD3 bispecific are recruiting [3][4], an unusually aggressive design choice for a sponsor cannibalizing its own franchise.

This is a novel biologic, first-in-class in the trispecific T-cell engager category. The originally linked NCT05652335 is the Phase 1 first-in-human dose-escalation and expansion study; interim data (Rodriguez-Otero et al., ASCO 2025) established the RP2D and reported an ORR of 73% (66% ≥VGPR) across 124 response-evaluable patients, with median time to first response of 1.2 months and CRS predominantly grade 1 [16]. The program has since advanced. Two Phase 3 trials are recruiting: NCT07258511 (n=400, versus an anti-BCMAxCD3 bispecific, primary endpoint overall response) and NCT07518186 (n=700, direct head-to-head versus teclistamab, primary endpoint complete response or better) [3][4]. Total Phase 3 enrollment across both trials is approximately 1,100 patients. A Phase 2 monotherapy study (NCT07266441, n=168) is active [5]. Combination work with daratumumab plus lenalidomide or pomalidomide is running in Phase 1 (NCT06768489) [6], and a dedicated Phase 2 evaluates prophylactic tocilizumab to blunt cytokine release syndrome (NCT07589634) [7]. NCT07-series numbers were registered in late 2025-2026 and remain the primary source for design details; readers should confirm the current status on ClinicalTrials.gov before acting. Public FDA designations (breakthrough, fast track, orphan) are not confirmed for this asset. Readouts from the Phase 3 head-to-heads are expected in the 2027-2029 window based on trial timing.

Multiple myeloma is a cancer of plasma cells, the antibody factories that live in bone marrow. BCMA (technically TNFRSF17) sits on the surface of nearly all myeloma cells and normally receives survival signals from the immune system [8]. GPRC5D is a second protein that also decorates myeloma cells but is largely absent from normal tissue except hair and tongue [9]. CD3 is the trigger on T cells. A T-cell engager works like molecular double-sided tape: one end grabs the cancer cell, the other end grabs a T cell, forcing them into contact so the T cell kills the tumor. Teclistamab (Tecvayli, J&J) does this with BCMA only [10]. Talquetamab (Talvey, J&J) does it with GPRC5D only [11]. Both work, but patients relapse when their myeloma stops expressing the single target, a phenomenon called antigen escape and now documented in post-teclistamab biopsies [12]. Ramantamig is a single engineered antibody scaffold carrying three distinct binding domains: one arm binds BCMA, a second arm binds GPRC5D, and a third arm binds CD3, with the CD3 arm intentionally engineered for low affinity to reduce off-tumor T-cell activation [15]. A tumor cell therefore has to lose both BCMA and GPRC5D to escape recognition. The mechanism is genetically and clinically validated at each individual target; the trispecific format is the novel bet.

The Phase 3 program is unusually confrontational. NCT07518186 pits JNJ-79635322 directly against teclistamab, J&J's own approved BCMAxCD3 bispecific, with complete response or better as the primary endpoint in 700 patients [4]. That is an internal cannibalization trial: J&J is willing to displace Tecvayli revenue if the trispecific is meaningfully better on response depth. NCT07258511 (n=400) uses a similar active-comparator design against another anti-BCMAxCD3 bispecific with overall response as the endpoint [3]. Both are open-label, which is standard for these agents given the CRS management protocols. The Phase 2 monotherapy trial (NCT07266441) will read out first and is the near-term catalyst [5]. Enrollment health across the program appears healthy given the number of parallel studies J&J is running, though specific site activation and accrual rates have not been disclosed. The tocilizumab prophylaxis study (NCT07589634) is a tell: J&J anticipates CRS will be the main outpatient-administration barrier and is running the pivotal safety-management study in parallel rather than post-approval [7]. Because the four NCT07-series identifiers post-date the mid-2025 ClinicalTrials.gov range, downstream users should verify each record before quoting design details in a decision context.

Our model estimates a 52% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design, its light or open-label blinding, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk sits in the dual-target thesis. If antigen escape is not the dominant resistance mechanism after BCMA bispecifics (T-cell exhaustion and tumor microenvironment factors also matter), then adding GPRC5D targeting may not translate into deeper or more durable responses [12]. Safety risk is concrete: BCMAxCD3 bispecifics carry approximately 70% CRS rates in MajesTEC-1 and a documented infection signal driven by hypogammaglobulinemia (low serum antibody levels causing susceptibility to bacterial and viral infection); GPRC5DxCD3 agents add dysgeusia, skin toxicity, and nail changes seen with talquetamab [10][11]. Stacking two tumor-engagement arms could amplify CRS on first dose, which is why the tocilizumab prophylaxis study exists [7]. Phase 1 CRS was predominantly grade 1 [16], which is encouraging, but Phase 3 populations are larger and less selected. Regulatory risk is modest given the class precedent, but the FDA will want clean differentiation from Tecvayli to justify a new Biologics License Application (BLA, the FDA pathway for antibody drugs). Commercial risk is the sharpest edge: even if approved, JNJ-79635322 has to displace teclistamab and elranatamab (Pfizer) and compete with CAR-T options like cilta-cel (Carvykti, J&J/Legend) and ide-cel (Abecma, BMS). J&J's own Tecvayli generated $549M in 2024 sales against total J&J revenues of $88.8B [14]; cannibalizing that product only makes sense if the trispecific captures earlier lines of therapy where CAR-T logistics are a barrier. Patent and regulatory-exclusivity timing for ramantamig is not publicly disclosed at the compound level; assume standard 12-year biologic reference-product exclusivity from first approval plus composition-of-matter patents extending into the late 2030s, subject to confirmation.

Worth watching, and specifically the Phase 2 monotherapy readout from NCT07266441 is the next signal that matters [5]. The key data point: complete response rate and MRD-negativity (minimal residual disease negativity - no detectable myeloma cells by high-sensitivity assay, typically 10^-5 or 10^-6) depth in triple-class-exposed patients (patients who have already progressed on an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody like daratumumab), ideally including a subset who received prior BCMA-directed therapy. The Phase 1 signal - 100% ORR and 89% ≥VGPR in naive patients at RP2D - is strong, but Phase 2 will test whether that translates into deep, durable responses in the pretreated population that matters commercially [16]. If Phase 2 confirms the depth, the Phase 3 head-to-heads become high-conviction; if not, the trispecific is a marginal improvement that has to fight for share against three approved bispecifics, two CAR-Ts, and daratumumab combinations. Check back after ASH 2026 or ASH 2027 for that Phase 2 readout. Approval and launch timeline: assuming Phase 3 readouts in 2027-2029 and standard BLA review, first approval is realistic in the 2029-2031 window. Peak sales potential is not disclosed by J&J; class comparators suggest a low-to-mid single-digit-billion-dollar ceiling in relapsed/refractory MM before considering earlier-line expansion, but this is a directional estimate rather than a company guidance figure. Corporate context: J&J is the dominant myeloma franchise holder with Darzalex, Tecvayli, Talvey, and Carvykti; running a trial that could disrupt Tecvayli signals real confidence in the asset, not defensive positioning. This is not investment advice.